AMPK activators as novel therapeutics for type 2 diabetes

Current Topics in Medicinal Chemistry

Volumn 10, Issue 4, 2010, Pages 397-410

  Yu, Li Fang ^a   Qiu, Bei Ying ^a   Nan, Fa Jun ^a   Li, Jia ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; A 592017; ADENYLATE KINASE; ANTIDIABETIC AGENT; BENZIMIDAZOLE DERIVATIVE; BERBERINE; CARBOXYLIC ACID DERIVATIVE; COMBRETASTATIN A4; D 942; DHBERBERINE; FURANCARBOXYLIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; IMIDAZOPYRIDINE DERIVATIVE; KETONE DERIVATIVE; METFORMIN; NOOTKATONE; PIOGLITAZONE; POLYPHENOL DERIVATIVE; PT 1; QUINAZOLINE DERIVATIVE; RESVERATROL; ROSIGLITAZONE; S 17834; S 27847; SESQUITERPENE DERIVATIVE; THIAZOLE DERIVATIVE; THIENOPYRIDINE DERIVATIVE; TRITERPENOID; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIGAND;

ADIPOSE TISSUE; BIOGENESIS; CELL CYCLE ARREST; DIABETES MELLITUS; DIARRHEA; DISEASE MODEL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FATTY LIVER; FLUID RETENTION; GLUCONEOGENESIS; GLUCOSE TRANSPORT; HEART FAILURE; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; LIVER; MITOCHONDRION; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SUBSTITUTION REACTION; TREATMENT OUTCOME; WEIGHT GAIN; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLIC DISEASES; STRUCTURE ACTIVITY RELATION;

AMP-ACTIVATED PROTEIN KINASES; DIABETES MELLITUS, TYPE 2; HUMANS; LIGANDS; METABOLIC DISEASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949471535     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610790980611     Document Type: Review

References (88)

1. Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004, 27, 1047-1053.
2. Hardie, D. G.; Carling, D.; Carlson, M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu. Rev. Biochem., 1998, 67, 821-855.
3. Pang, T.; Xiong, B.; Li, J. Y.; Qiu, B. Y.; Jin, G. Z.; Shen, J. K.; Li, J. Conserved alpha-helix acts as autoinhibitory sequence in AMP-activated protein kinase alpha subunits. J. Biol. Chem., 2007, 282, 495-506.
4. Crute, B. E.; Seefeld, K.; Gamble, J.; Kemp, B. E.; Witters, L. A. Functional domains of the alpha1 catalytic subunit of the AMP-activated protein kinase. J. Biol. Chem., 1998, 273, 35347-35354.
5. Hardie, D. G. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol., 2007, 8, 774-785.
6. Bateman, A. The structure of a domain common to archaebacteria and the homocystinuria disease protein. Trends Biochem. Sci., 1997, 22, 12-13.
7. Scott, J. W.; Hawley, S. A.; Green, K. A.; Anis, M.; Stewart, G.; Scullion, G. A.; Norman, D. G.; Hardie, D. G. CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J. Clin. Invest, 2004, 113, 274-284.
8. Hawley, S. A.; Pan, D. A.; Mustard, K. J.; Ross, L.; Bain, J.; Edelman, A. M.; Frenguelli, B. G.; Hardie, D. G. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab., 2005, 2, 9-19.
9. Hawley, S. A.; Boudeau, J.; Reid, J. L.; Mustard, K. J.; Udd, L.; Makela, T. P.; Alessi, D. R.; Hardie, D. G. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol., 2003, 2, 28.
10. Momcilovic, M.; Hong, S. P.; Carlson, M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J. Biol. Chem., 2006, 281, 25336-25343.
11. Towler, M. C.; Hardie, D. G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ. Res., 2007, 100, 328-341.
12. Hardie, D. G. AMP-activated protein kinase as a drug target. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 185-210.
13. Winder, W. W.; Hardie, D. G. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am. J. Physiol., 1999, 277, E1-10.
14. Foretz, M.; Ancellin, N.; Andreelli, F.; Saintillan, Y.; Grondin, P.; Kahn, A.; Thorens, B.; Vaulont, S.; Viollet, B. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes, 2005, 54, 1331-1339.
15. LeBrasseur, N. K.; Kelly, M.; Tsao, T. S.; Farmer, S. R.; Saha, A. K.; Ruderman, N. B.; Tomas, E. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am. J. Physiol. Endocrinol. Metab., 2006, 291, E175-181.
16. Musi, N.; Hirshman, M. F.; Nygren, J.; Svanfeldt, M.; Bavenholm, P.; Rooyackers, O.; Zhou, G.; Williamson, J. M.; Ljunqvist, O.; Efendic, S.; Moller, D. E.; Thorell, A.; Goodyear, L. J. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes, 2002, 51, 2074-2081.
17. Cheon, H. G.; Kim, K. R.; Rhee, S. D.; Jung, W. H.; Lee, J. C.; Lee, J. H.; Lee, K.; Kim, S. W.; Jun, S. S. Furan-2-carboxylic acid derivatives and process for the preparation thereo, PCT. Appl. WO2008/016278 A1, Aug. 3, 2008.
18. Porluri, V. K.; Das, S. K.; Sasmal, P. K.; Iqbal, J.; Misra, P.; Chakrabarti, R.; Ralwar, R. Thiazole derivativies as AMPK activator, PCT Int. Appl. US2006/025898 A1, Jun. 30, 2006.
19. Cool, B.; Zinker, B.; Chiou, W.; Kifle, L.; Cao, N.; Perham, M.; Dickinson, R.; Adler, A.; Gagne, G.; Iyengar, R.; Zhao, G.; Marsh, K.; Kym, P.; Jung, P.; Camp, H. S.; Frevert, E. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab., 2006, 3, 403-416.
20. Pang, T.; Zhang, Z. S.; Gu, M.; Qiu, B. Y.; Yu, L. F.; Cao, P. R.; Shao, W.; Su, M. B.; Li, J. Y.; Nan, F. J.; Li, J. Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. J. Biol. Chem., 2008, 283, 16051-16060.
21. Sabina, R. L.; Patterson, D.; Holmes, E. W. 5-Amino-4- imidazolecarboxamide riboside (Z-riboside) metabolism in eukaryotic cells. J. Biol. Chem., 1985, 260, 6107-6114.
22. Carling, D. Ampk. Curr. Biol., 2004, 14, R220.
23. Hardie, D. G. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology, 2003, 144, 5179-5183.
24. Corton, J. M.; Gillespie, J. G.; Hawley, S. A.; Hardie, D. G. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem., 1995, 229, 558-565.
25. Sullivan, J. E.; Brocklehurst, K. J.; Marley, A. E.; Carey, F.; Carling, D.; Beri, R. K. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett., 1994, 353, 33-36.
26. Merrill, G. F.; Kurth, E. J.; Hardie, D. G.; Winder, W. W. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am. J. Physiol., 1997, 273, E1107-1112.
27. Bergeron, R.; Russell, R. R. 3 rd.; Young, L. H.; Ren, J. M.; Marcucci, M.; Lee, A.; Shulman, G. I. Effect of AMPK activation on muscle glucose metabolism in conscious rats. Am. J. Physiol., 1999, 276, E938-944.
28. Hayashi, T.; Hirshman, M. F.; Kurth, E. J.; Winder, W. W.; Goodyear, L. J. Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes, 1998, 47, 1369-1373.
29. Russell, R. R., 3rd; Bergeron, R.; Shulman, G. I.; Young, L. H. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am. J. Physiol., 1999, 277, H643-649.
30. Mu, J.; Brozinick, J. T.Jr.; Valladares, O.; Bucan, M.; Birnbaum, M. J. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol. Cell, 2001, 7, 1085-1094.
31. Lochhead, P. A.; Salt, I. P.; Walker, K. S.; Hardie, D. G.; Sutherland, C. 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes, 2000, 49, 896-903.
32. Vincent, M. F.; Marangos, P. J.; Gruber, H. E.; Van den Berghe, G. Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes. Diabetes, 1991, 40, 1259-1266.
33. Holmes, B. F.; Kurth-Kraczek, E. J.; Winder, W. W. Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J. Appl. Physiol., 1999, 87, 1990-1995.
34. Song, X. M.; Fiedler, M.; Galuska, D.; Ryder, J. W.; Fernstrom, M.; Chibalin, A. V.; Wallberg-Henriksson, H.; Zierath, J. R. 5-Aminoimidazole-4- carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia, 2002, 45, 56-65.
35. Bergeron, R.; Previs, S. F.; Cline, G. W.; Perret, P.; Russell, R. R., 3rd; Young, L. H.; Shulman, G. I. Effect of 5-aminoimidazole-4-carboxamide-1- beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes, 2001, 50, 1076-1082.
36. Iglesias, M. A.; Ye, J. M.; Frangioudakis, G.; Saha, A. K.; Tomas, E.; Ruderman, N. B.; Cooney, G. J.; Kraegen, E. W. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes, 2002, 51, 2886-2894.
37. Vincent, M. F.; Erion, M. D.; Gruber, H. E.; Van den Berghe, G. Hypoglycaemic effect of AICAriboside in mice. Diabetologia, 1996, 39, 1148-1155.
38. Musi, N.; Goodyear, L. J. Targeting the AMP-activated protein kinase for the treatment of type 2 diabetes. Curr. Drug Targets Immune. Endocr. Metabol. Disord., 2002, 2, 119-127.
39. Iyengar, R. R. J.; udd, A. S.; Zhao, G.; Kym, P. R.; Sham, H. L.; Gu, Y.; Liu, G.; Liu, M.; Zhao, H.; Chark, R. F.; Frevert, E. U.; Cool, B. L.; Zhang, T.; Keyes, R. F.; Hansen, T. M.; Xin, Z. Thienopyridones as AMPK activators for the treatment of diabetes and obesity, PCT Int. Appl. US2005/0038068 A1, Feb. 17, 2005.
40. Zhao, G.; Iyengar, R. R.; Judd, A. S.; Cool, B.; Chiou, W.; Kifle, L.; Frevert, E.; Sham, H.; Kym, P. R. Discovery and SAR development of thienopyridones: a class of small molecule AMPK activators. Bioorg. Med. Chem. Lett., 2007, 17, 3254-3257.
41. Goransson, O.; McBride, A.; Hawley, S. A.; Ross, F. A.; Shpiro, N.; Foretz, M.; Viollet, B.; Hardie, D. G.; Sakamoto, K. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J. Biol. Chem., 2007, 282, 32549-32560.
42. Sanders, M. J.; Ali, Z. S.; Hegarty, B. D.; Heath, R.; Snowden, M. A.; Carling, D. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J. Biol. Chem., 2007, 282, 32539-32548.
43. Viana, R.; Aguado, C.; Esteban, I.; Moreno, D.; Viollet, B.; Knecht, E.; Sanz, P. Role of AMP-activated protein kinase in autophagy and proteasome function. Biochem. Biophys. Res. Commun., 2008, 369, 964-968.
44. Moreno, D.; Knecht, E.; Viollet, B.; Sanz, P. A769662, a novel activator of AMP-activated protein kinase, inhibits non-proteolytic components of the 26S proteasome by an AMPK-independent mechanism. FEBS Lett., 2008, 582, 2650-2654.
45. Hallakoubozec, S.; Charon, C.; Hock, B.; Poeschke, O. Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them, PCT Int. Appl. WO2007/019914, Feb 22, 2006.
46. Nan, FJ.; Li, J.; Liu, B.; Pang, T.; Yu, L. F.; Li, J.Y. Compounds used as mamalian cell AMP-activated protein kinase(AMPK) activators and their preparation methods and usages PCT Int. Appl. WO/2007/062568 A1, Dec. 10, 2006.
47. Moinet, G.; Marais, D.; Hallakou-bozec, S.; Charon, C. Use of AMPK-activating imidazole derivation preparation process therefore and pharamaceutical compositions comprising them, PCT Int. Appl. WO2008/006432 A1, Jun. 12, 2007.
48. Kirpichnikov, D.; McFarlane, S. I.; Sowers, J. R. Metformin: an update. Ann. Intern. Med., 2002, 137, 25-33.
49. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M. F.; Goodyear, L. J.; Moller, D. E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest, 2001, 108, 1167-1174.
50. Zang, M.; Zuccollo, A.; Hou, X.; Nagata, D.; Walsh, K.; Herscovitz, H.; Brecher, P.; Ruderman, N. B.; Cohen, R. A. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J. Biol. Chem., 2004, 279, 47898-47905.
51. Shaw, R. J.; Lamia, K. A.; Vasquez, D.; Koo, S. H.; Bardeesy, N.; Depinho, R. A.; Montminy, M.; Cantley, L. C. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 2005, 310, 1642-1646.
52. Hawley, S. A.; Gadalla, A. E.; Olsen, G. S.; Hardie, D. G. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes, 2002, 51, 2420-2425.
53. El-Mir, M. Y.; Nogueira, V.; Fontaine, E.; Averet, N.; Rigoulet, M.; Leverve, X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem., 2000, 275, 223-228.
54. Zou, M. H.; Kirkpatrick, S. S.; Davis, B. J.; Nelson, J. S.; Wiles, W. G. t.; Schlattner, U.; Neumann, D.; Brownlee, M.; Freeman, M. B.; Goldman, M. H. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J. Biol. Chem., 2004, 279, 43940-43951.
55. Bailey, C. J.; Turner, R. C. Metformin. N. Engl. J. Med., 1996, 334, 574-579.
56. Inzucchi, S. E.; Maggs, D. G.; Spollett, G. R.; Page, S. L.; Rife, F. S.; Walton, V.; Shulman, G. I. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N. Engl. J. Med., 1998, 338, 867-872.
57. Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem., 1995, 270, 12953-12956.
58. Maeda, N.; Takahashi, M.; Funahashi, T.; Kihara, S.; Nishizawa, H.; Kishida, K.; Nagaretani, H.; Matsuda, M.; Komuro, R.; Ouchi, N.; Kuriyama, H.; Hotta, K.; Nakamura, T.; Shimomura, I.; Matsuzawa, Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes, 2001, 50, 2094-2099.
59. Castelein, H.; Gulick, T.; Declercq, P. E.; Mannaerts, G. P.; Moore, D. D.; Baes, M. I. The peroxisome proliferator activated receptor regulates malic enzyme gene expression. J. Biol. Chem., 1994, 269, 26754-26758.
60. Guan, H. P.; Li, Y.; Jensen, M. V.; Newgard, C. B.; Steppan, C. M.; Lazar, M. A. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat. Med., 2002, 8, 1122-1128.
61. Lee, M. K.; Olefsky, J. M. Acute effects of troglitazone on in vivo insulin action in normal rats. Metabolism, 1995, 44, 1166-1169.
62. Burant, C. F.; Sreenan, S.; Hirano, K.; Tai, T. A.; Lohmiller, J.; Lukens, J.; Davidson, N. O.; Ross, S.; Graves, R. A. Troglitazone action is independent of adipose tissue. J. Clin. Invest, 1997, 100, 2900-2908.
63. Brunmair, B.; Staniek, K.; Gras, F.; Scharf, N.; Althaym, A.; Clara, R.; Roden, M.; Gnaiger, E.; Nohl, H.; Waldhausl, W.; Furnsinn, C. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes, 2004, 53, 1052-1059.
64. Kosaka, T.; Okuyama, R.; Sun, W.; Ogata, T.; Harada, J.; Araki, K.; Izumi, M.; Yoshida, T.; Okuno, A.; Fujiwara, T.; Ohsumi, J.; Ichikawa, K. Identification of molecular target of AMP-activated protein kinase activator by affinity purification and mass spectrometry. Anal Chem., 2005, 77, 2050-2055.
65. Charton, J.; Girault-Mizzi, S.; Debreu-Fontaine, M.; Foufelle, F.; Hainault, I.; Bizot-Espiard, J.; Caignardc, D.; Sergheraert, C. Synthesis and biological evaluation of benzimidazole derivatives as potent AMP-activated protein kinase activators Bioorg. Med. Chem., 2006, 14, 4490-4518.
66. Rault, S.; Lancelot, J. C.; Kopp, M.; Caingnard, D. H.; Pfeiffer, B.; Renard, P.; Bizot-espiard, J. G. Imidazopyridine derivatives, prepararion method and pharmaceutical compositions containing same, PCT Int. Appl. WO2004/043957 A1, Nov. 4, 2003.
67. Lee, N. K.; Lee, J. W.; Lee, S.; Im, G. J.; Han, H. Y.; Kim, T. K.; Kim, Y. H.; Kwak, W. J.; Kim, S. W.; Ha, J.; Kim, E. K.; Lee, J. K.; Yoo, C. Y.; Lee, D. Y. Quinazoline derivatives for the treatment and prevention of diabetes and obesity, PCT Int. Appl. WO2006/071095 A1, Dec. 30, 2005.
68. Takatoshi, M.; Yoshihiko, M. AMPK activating agent, US2007054965, Mar. 8, 2007.
69. Koehn, F. E.; Carter, G. T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov., 2005, 4, 206-220.
70. Kong, W.; Wei, J.; Abidi, P.; Lin, M.; Inaba, S.; Li, C.; Wang, Y.; Wang, Z.; Si, S.; Pan, H.; Wang, S.; Wu, J.; Wang, Y.; Li, Z.; Liu, J.; Jiang, J. D. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med., 2004, 10, 1344-1351.
71. Lee, Y. S.; Kim, W. S.; Kim, K. H.; Yoon, M. J.; Cho, H. J.; Shen, Y.; Ye, J. M.; Lee, C. H.; Oh, W. K.; Kim, C. T.; Hohnen-Behrens, C.; Gosby, A.; Kraegen, E. W.; James, D. E.; Kim, J. B. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes, 2006, 55, 2256-2264.
72. Cheng, Z.; Pang, T.; Gu, M.; Gao, A. H.; Xie, C. M.; Li, J. Y.; Nan, F. J.; Li, J. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim. Biophys. Acta, 2006, 1760, 1682-1689.
73. Turner, N.; Li, J. Y.; Gosby, A.; To, S. W.; Cheng, Z.; Miyoshi, H.; Taketo, M. M.; Cooney, G. J.; Kraegen, E. W.; James, D. E.; Hu, L. H.; Li, J.; Ye, J. M. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes, 2008, 57, 1414-1418.
74. Yin, J.; Gao, Z.; Liu, D.; Liu, Z.; Ye, J. Berberine improves glucose metabolism through induction of glycolysis. Am. J. Physiol. Endocrinol. Metab., 2008, 294, E148-156.
75. Zang, M.; Xu, S.; Maitland-Toolan, K. A.; Zuccollo, A.; Hou, X.; Jiang, B.; Wierzbicki, M.; Verbeuren, T. J.; Cohen, R. A. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes, 2006, 55, 2180-2191.
76. Collins, Q. F.; Liu, H. Y.; Pi, J.; Liu, Z.; Quon, M. J.; Cao, W. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5′-AMP-activated protein kinase. J. Biol. Chem., 2007, 282, 30143-30149.
77. Park, C. E.; Kim, M. J.; Lee, J. H.; Min, B. I.; Bae, H.; Choe, W.; Kim, S. S.; Ha, J. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp. Mol. Med., 2007, 39, 222-229.
78. Baur, J. A.; Pearson, K. J.; Price, N. L.; Jamieson, H. A.; Lerin, C.; Kalra, A.; Prabhu, V. V.; Allard, J. S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P. J.; Poosala, S.; Becker, K. G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K. W.; Spencer, R. G.; Lakatta, E. G.; Le Couteur, D.; Shaw, R. J.; Navas, P.; Puigserver, P.; Ingram, D. K.; de Cabo, R.; Sinclair, D. A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006, 444, 337-342.
79. Dasgupta, B.; Milbrandt, J. Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl. Acad. Sci. USA, 2007, 104, 7217-7222.
80. Zhang, F.; Sun, C.; Wu, J.; He, C.; Ge, X.; Huang, W.; Zou, Y.; Chen, X.; Qi, W.; Zhai, Q. Combretastatin A-4 activates AMP-activated protein kinase and improves glucose metabolism in db/db mice. Pharmacol. Res., 2008, 57, 318-323.
81. Koyama, Y.; Abe, K.; Sano, Y.; Ishizaki, Y.; Njelekela, M.; Shoji, Y.; Hara, Y.; Isemura, M. Effects of green tea on gene expression of hepatic gluconeogenic enzymes in vivo. Planta Med., 2004, 70, 1100-1102.
82. Anton, S.; Melville, L.; Rena, G. Epigallocatechin gallate (EGCG) mimics insulin action on the transcription factor FOXO1a and elicits cellular responses in the presence and absence of insulin. Cell Signal., 2007, 19, 378-383.
83. Yang, G. Y.; Liao, J.; Li, C.; Chung, J.; Yurkow, E. J.; Ho, C. T.; Yang, C. S. Effect of black and green tea polyphenols on c-jun phosphorylation and H(2)O(2) production in transformed and nontransformed human bronchial cell lines: possible mechanisms of cell growth inhibition and apoptosis induction. Carcinogenesis, 2000, 21, 2035-2039.
84. Tan, M. J.; Ye, J. M.; Turner, N.; Hohnen-Behrens, C.; Ke, C. Q.; Tang, C. P.; Chen, T.; Weiss, H. C.; Gesing, E. R.; Rowland, A.; James, D. E.; Ye, Y. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem. Biol., 2008, 15, 263-273.
85. Grover, J. K.; Yadav, S. P. Pharmacological actions and potential uses of Momordica charantia: a review. J. Ethnopharmacol., 2004, 93, 123-132.
86. Huang, S.; Czech, M. P. The GLUT4 glucose transporter. Cell Metab., 2007, 5, 237-252.
87. Hwang, J. T.; Kim, S. H.; Lee, M. S.; Kim, S. H.; Yang, H. J.; Kim, M. J.; Kim, H. S.; Ha, J.; Kim, M. S.; Kwon, D. Y. Anti-obesity effects of ginsenoside Rh2 are associated with the activation of AMPK signaling pathway in 3T3-L1 adipocyte. Biochem. Biophys. Res. Commun., 2007, 364, 1002-1008.
88. Park, M. W.; Ha, J.; Chung, S. H. 20(S)-ginsenoside Rg3 enhances glucose-stimulated insulin secretion and activates AMPK. Biol. Pharm. Bull., 2008, 31, 748-751.